IL132145A - Compositions for treating inflammatory bowel disease and uses thereof - Google Patents

Compositions for treating inflammatory bowel disease and uses thereof

Info

Publication number
IL132145A
IL132145A IL13214598A IL13214598A IL132145A IL 132145 A IL132145 A IL 132145A IL 13214598 A IL13214598 A IL 13214598A IL 13214598 A IL13214598 A IL 13214598A IL 132145 A IL132145 A IL 132145A
Authority
IL
Israel
Prior art keywords
compositions
inflammatory bowel
bowel disease
treating inflammatory
treating
Prior art date
Application number
IL13214598A
Other languages
English (en)
Other versions
IL132145A0 (en
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of IL132145A0 publication Critical patent/IL132145A0/xx
Publication of IL132145A publication Critical patent/IL132145A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13214598A 1997-04-01 1998-04-01 Compositions for treating inflammatory bowel disease and uses thereof IL132145A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
IL132145A0 IL132145A0 (en) 2001-03-19
IL132145A true IL132145A (en) 2005-11-20

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13214598A IL132145A (en) 1997-04-01 1998-04-01 Compositions for treating inflammatory bowel disease and uses thereof

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
EP1150666B1 (en) * 1999-02-12 2009-10-28 Washington University Gm-csf for the treatment of crohn's disease
DE60017180T2 (de) 1999-10-08 2005-12-08 Affinium Pharmaceuticals, Inc., Toronto Fab i inhibitoren
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
IL151888A0 (en) * 2000-03-28 2003-04-10 Biochemie Gmbh Granulated particles with masked taste
ES2333337T3 (es) 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
AU2003298937A1 (en) * 2002-12-06 2004-06-30 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
CA2553775A1 (en) * 2004-01-20 2005-08-11 Richard F. Harty Compositions and methods of treatment for inflammatory diseases
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
EP3391882A1 (en) * 2008-02-08 2018-10-24 Red Hill Biopharma Ltd. Compositions comprising rifabutin, clarithromycin, and clofazimine
CA2721981A1 (en) * 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
CA2778181C (en) 2009-10-26 2024-05-28 Thomas Julius Borody Therapy for enteric infections
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
CA2821196C (en) 2010-12-13 2022-11-22 Thomas Julius Borody Gastric and colonic formulations and methods for making and using them
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
DK2861608T3 (da) 2012-06-19 2019-06-24 Debiopharm Int Sa Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
ES2717282T3 (es) 2012-07-27 2019-06-20 Redhill Biopharma Ltd Formulaciones y métodos para fabricar formulaciones para su uso en la evacuación colónica
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
BR112018016721A2 (pt) 2016-02-26 2018-12-26 Debiopharm Int Sa uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CA3139942A1 (en) 2019-06-14 2020-12-17 Justyna NOWAKOWSKA Medicament and use thereof for treating bacterial infections involving biofilm
US11590154B2 (en) 2020-06-30 2023-02-28 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
ATE389417T1 (de) 2008-04-15
ES2303351T3 (es) 2008-08-01
PT971735E (pt) 2008-06-02
EP0971735B1 (en) 2008-03-19
JP2008024713A (ja) 2008-02-07
EP0971735A4 (en) 2004-02-25
JP2012126736A (ja) 2012-07-05
NZ500696A (en) 2002-05-31
JP2001524951A (ja) 2001-12-04
CY1109783T1 (el) 2013-09-04
SI0971735T1 (sl) 2008-08-31
DE69839261D1 (de) 2008-04-30
DK0971735T3 (da) 2008-07-07
NO994778D0 (no) 1999-09-30
NO325947B1 (no) 2008-08-25
AR012304A1 (es) 2000-10-18
EP0971735A1 (en) 2000-01-19
US6277836B1 (en) 2001-08-21
CA2285923A1 (en) 1998-10-08
DE69839261T2 (de) 2009-03-26
WO1998043667A1 (en) 1998-10-08
IL132145A0 (en) 2001-03-19
CA2285923C (en) 2013-03-12
NO994778L (no) 1999-11-30

Similar Documents

Publication Publication Date Title
IL132145A (en) Compositions for treating inflammatory bowel disease and uses thereof
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
ZA98454B (en) Personal cleansing compositions
PL336840A1 (en) Hair-care composition
EP0766564A4 (en) SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
IL127636A0 (en) Polyester compositions
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
EP1020194A4 (en) AQUEOUS TYPE EMULSION COMPOSITIONS
HUP0103562A3 (en) Novel compositions and use
ZA98455B (en) Personal cleansing compositions
PL336349A1 (en) Compositions for and methods for treating and diagnosing the mastocarcinoma
GB9720797D0 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
AU6386499A (en) Method and composition for treatment of inflammatory bowel disease
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
GB9901577D0 (en) Polyester compositions
PL330353A1 (en) Detergent hair-care compositions and their application
IL120488A (en) Modifiers for water-setting inorganic compositions and modified water-setting inorganic compositions
HUP0400922A3 (en) Detergent compositions and their use
GB9824450D0 (en) Malodour counteractant compositions
ZA982645B (en) Methods and compositions for treating inflammatory bowel disease
PL342253A1 (en) Pharmacological compositions based on bibapticide for visualising and treating thrombuses
PL338379A1 (en) Novel photoinitiators and their application
GB9725346D0 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
GB9701041D0 (en) Treatment of inflammatory bowel conditions
AUPO978597A0 (en) Methods of treating inflammatory bowel disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired